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Accessory spleens are congenital abnormalities, being identi-
fied in approximately 7–15% of population. Their most frequent 
location is splenic hilum, pancreatic tail, gastro-splenic ligament, 
intestinal wall, mesentery, greater omentum or uterine appendages.
Intrapancreatic accessory spleens (IPAS) usually pose no clini-
cal problem. With the development of improved imaging techniques, 
IPAS are more readily detected. The occasional findings may mimic 
other types of a mass-forming lesion in the tail of the pancreas, 
particular pancreatic neuroendocrine neoplasms (pNEN), adeno-
carcinoma, pseudopapillary tumors and metastases. 
We report a case of 40-year-old woman with history of gastroe-
sophageal reflux disease admitted to the Clinic of Endocrinology with 
a suspicion of serotonin-secreting neuroendocrine neoplasm. She 
reported an atypical symptoms of carcinoid syndrome such as spo-
radic but intensive flushing, fatigue and weight loss of approximately 
4–5 kg for 5 years. Her family history was unremarkable. She reported 
the use of proton pomp inhibitor esomeprazole 40 mg daily.
A physical examination and additional laboratory data find-
ings were unremarkable. Level of serum chromogranin A was 
elevated (346 µg/dL; normal: 0–94 µg/dL), however normalized after 
cessation of proton pomp inhibitor therapy. The concentration of 
5-hydroxyindoloacetic acid (5-HIAA) in 24-hour urine collection 
was in normal range. 
Abdomen computed tomography (CT) scans showed round 
homogenous lesion of 20 mm in diameter located in the distal part 
of the tail of the pancreas with the intensive arterial enhancement 
(Figure 1). In further diagnostic procedure, magnetic resonance im-
aging (MRI) of the abdomen was performed and revealed a 17 mm 
well-defined mass with spleen-like low signal intensity on T1 (Figure 
2A), T2-hyperintense fat saturated images (Figure 2B) and significant 
heterogeneous contrast enhancement in arterial phase, followed by 
Figure 1. 
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homogeneous enhancement in venous and delayed phases. Based 
on radiographic findings, pNEN, IPAS or pseudopapillary tumor were 
suspected. Gallium-68 (68Ga-DOTA-TATE) PET/CT revealed a mass in 
the tail of pancreas with intensive uptake of the tracer (Figure 3). En-
doscopic ultrasonography (EUS) was performed and demonstrated 
the oval shaped, well-defined, and homogeneous, hypoechoic lesion 
in the tail of the pancreas, which presented similar echogenicity 
to the spleen. A cytological result of fine needle aspiration (FNA) 
biopsy showed large aggregates of plasma cells leukocyte count, 
with no epithelium cell and the cell block were immunonegative for 
synaptophysin and chromogranin.
Since the etiology of the mass in the tail of the pancreas re-
mains unclear, technetium-99m Single-photon emission computed 
tomography (SPECT) using 99mTc-labelled tin colloid (PoltechCol-
loid, NCBJ, Polatom, PL), was performed to differentiate spleen 
tissue from neuroendocrine tumour. The high uptake of radiotracer 
in suspicious mass in the pancreatic distal tail close to spleen hilum 
was consistent with accessory spleen (Figure 4).
Figure 3. 
Figure 4. 
Considering the patient’s diagnostic process, we suggest that 
clinical and radiological approach is essential for making the correct 
diagnosis of IPAS leading to a good prognosis and prevention of 
unnecessary medical procedures.
